SR One Capital Management

Congratulations to #PortfolioCompany Dren Bio, Inc. on the acquisition of their potential first-in-class CD20-directed bispecific antibody by Sanofi. This acquisition marks a significant step forward in Dren Bio’s mission to deliver important new medicines that meaningfully improve the lives of people living with a variety of #autoimmune conditions and #cancer. We are honored to support this important work, both through our financial investment since the Series A and through our close partnership with the Dren team at the Board level with SR One Managing Partner Rajeev Dadoo and at the leadership level with SR One Venture Partner Amit Mehta as Chief Business Officer and Chief Operating Officer. Read the full release: https://lnkd.in/e9nSQP7A #biopharma #venturecapital #innovation

Celebrating International Women’s Day this week, we're proud to highlight Sheila Gujrathi, MD, co-founder of Biotech CEO Sisterhood, and her incredible contributions to empower and mentor the next generation of female leaders in biotech. See more inspiration from her TEDx talk, “Focus on the Mirror, Not the Glass Ceiling.”https://lnkd.in/devV9k6r #WomenInScience #TedTalk #STEM

We're highlighting portfolio company Avenzo Therapeutics and their efforts to transform the cancer treatment landscape.?? Learn more about their robust oncology pipeline: https://avenzotx.com/? ? See our entire portfolio: https://lnkd.in/gmgM5Chu? ? #VentureCapital #PortfolioCompany #VC?

This #InternationalWomensDay, we’re working to #AccelerateAction both in and outside of the workplace, as we work collaboratively to promote personal and professional spaces that are more inclusive, diverse and equitable. Meet some of our incredible team members who are at the forefront of these efforts in the biopharma and VC industry. ? Thank you for your leadership, Jill Carroll, Lynne Murray, Laetitia Schwab, Catalina Kazi, Marie Frances Benson, Alicia Hasson, Katarina Pance, PhD, Briana Wilson, Lyla Youssef, Ph.D., Bree Aguilar, Ann Ng, Janet Mastrocola, Karen Narolewski-Engel, Sasha Keough and Tanya Mcglashan. #VC #VentureCapital #IWD2025

“For us, this is an incredible moment in time. There's no shortage of scientific innovation.” SR One CEO, Simeon George, sat down with Simone Fishburn on The BioCentury Inc. Show Podcast. Hear more about Simeon’s perspective on the new normal in biotech financing and investing, and how the right leadership is critical to success. Watch it here: https://lnkd.in/gVddBhBG #biopharma #venturecapital #innovation

Today we’re spotlighting #portfolio company ADARx Pharmaceuticals Inc. and their efforts to advance a broad pipeline of next-generation #RNA medicines.? ?? With a goal of creating potent and precise RNA medicines, their hope is to make a meaningful difference in the lives of patients with chronic diseases.? ? Learn more about ADARx: https://www.adarx.com/? ? See our entire portfolio: https://lnkd.in/gmgM5Chu? ? #VentureCapital #PortfolioCompany #VC?

At SR One, our passion is focused on finding value for patients. ? We partner with entrepreneurs, founders and innovators who can identify and address gaps in the current treatment landscape to transform innovative science into medicine. ? https://www.srone.com ? #vc #biopharma #venturecapital

Proud to see Lynne Murray representing SR One Capital Management on the panel at the recent UK Biotech CEO community event! #Biotech #Innovation

Proud to see so many of our remarkable #portfoliocompanies represented at #JPM2025. Each year, the J.P. Morgan conference offers an opportunity for biopharma companies to engage in conversations about impactful science, groundbreaking innovations and emerging technologies that are poised to drive meaningful change in medicine for the year ahead. We are proud to support many of these companies and play a role in advancing health care. #JPM25 #VC #Innovation

Join us in welcoming venture partner Matthew Patterson to #TeamSROne. Matt will focus on US investments and brings 30 years of industry experience with a focus on advancing #innovative science targeting rare diseases. Previously, Matt?co-founded and served as CEO of Audentes Therapeutics. Join us in welcoming Matt to our team! Meet #TeamSROne: https://www.srone.com/team #VentureCapital #Investing #BioPharma